雾化吸入改善慢阻肺合并睡眠障碍患者临床结局OA

Objective:To explore the effect of combined nebulized inhalation therapy on clinical outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)complicated by sleep disorders,based on routine treatment.Methods:A total of 80 patients with AECOPD and Pittsburgh Sleep Quality Index(PSQI)scores＞7 admitted to Tonglu Hospital of Hangzhou First People's Hospital from January 2023 to January 2025 were enrolled and randomly divided into a con-trol group and an observation group,with 40 cases in each group.The control group received routine comprehensive treatment,while the observation group additionally received nebulized inhalation of budesonide,terbutaline,and ipratropium bromide twice daily.PSQI,Self-Rating Scale of Sleep(SRSS),modified Medical Research Council(mMRC)dyspnea scale,COPD Assessment Test(CAT),nighttime symptom Visual Analogue Scale(VAS),and pulmonary function indices were compared before and after treatment.Results:After treatment,the observation group showed significantly lower scores in PSQI(8.15±2.12 vs 10.82±2.36),SRSS(22.74±3.85 vs 26.87±4.02),mMRC(1.85±0.61 vs 2.31±0.68),CAT(17.34±3.85 vs 20.72±4.12),and nighttime VAS(4.12±1.05 vs 5.87±1.18)compared with the control group(all P＜0.05).Improvements in FEV1 and FEV1/FVC were also more significant in the observation group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:For patients with AECOPD complicated by sleep disorders,short-term intensified nebulized inhalation therapy in addition to routine treatment can further improve sleep quality,symptoms,pulmonary function,and quality of life,with good safety.